Corrigendum to “Systematic Understanding of the Mechanism of Baicalin against Ischemic Stroke through a Network Pharmacology Approach”

Xu, Tian; Ma, Chongyang; Fan, Shuning; Deng, Nan; Lian, Yajun; Tan, Ling; Du, Weizhe; Zhang, Shuang; Liu, Shilin; Ren, Beida; Li, Zhenhan; Wang, Qingguo; Wang, Xueqian; Cheng, Fang

doi:10.1155/2019/4520704

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic Target Database (TTD) ( https://db.idrblab.org/ttd/ ) explores therapeutic protein and nucleic acid targets within a targeted disease ( 14 ). DisGeNET ( http://www.disgenet.org/web/DisGeNET/menu/home ) is a discovery platform containing one of the largest publicly available collections of genes and variants associated with human diseases ( 15 ).…”

Section: Methodsmentioning

confidence: 99%

Network pharmacology‑based prediction of the active compounds and mechanism of Buyang Huanwu Decoction for ischemic stroke

et al. 2021

View full text Add to dashboard Cite

Buyang Huanwu Decoction (BYHWD) is used to promote blood circulation and is widely used in Chinese clinical practice for the treatment and prevention of ischemic cerebral vascular diseases. However, the mechanism and active compounds of BYHWD used to treat ischemic stroke are not well understood. The current study aimed to identify the potential active components of BYHWD and explore its mechanism using network pharmacology and bioinformatics analyses. The compounds of BYHWD were obtained from public databases. Oral bioavailability and drug-likeness were screened using the absorption, distribution, metabolism and excretion (ADME) criteria. Components of BYHWD, alongside the candidate targets of each component and the known therapeutic targets of ischemic stroke were collected. A network of target gene compounds and cerebral ischemia compounds was established using network pharmacology data sources. The enrichment of key targets and pathways was analyzed using STRING and DAVID databases. Moreover, three of key targets [IL6, VEGFA and hypoxia-inducible-factor-1α (HIF-1α)] were verified using western blot analysis. Network analysis determined 102 compounds in seven herbal medicines that were subjected to ADME screening. A total of 42 compounds as well as 79 genes formed the principal pathways associated with ischemic stroke. The 16 key compounds identified were baicalein, beta-carotene, baicalin, kaempferol, luteolin, quercetin, hydroxysafflor yellow A, isorhamnetin, bifendate, formononetin, calycosin, astragaloside IV, stigmasterol, sitosterol, Z-ligustilide, and dihydrocapsaicin. The core genes in this network were IL6, TNF, VEGFA, HIF-1α, MAPK1, MAPK3, JUN, STAT3, IL1B and IL10. Furthermore, the TNF, IL17, apoptosis, PI3K-Akt, toll-like receptor, MAPK, NF-κB and HIF-1 signaling pathways were identified to be associated with ischemic stroke. Compared with the control group (no treatment), BYHWD significantly inhibited the expression of IL6 and increase the expression of HIF-1α and VEGFA. Network pharmacology analyses can help to reveal close interactions between multi-components and multi-targets and enhance understanding of the potential effects of BYHWD on ischemic stroke.

show abstract

Section: Methodsmentioning

confidence: 99%